Phs 398 (rev. 9/04), biographical sketch format page

05/08 - Chaired Professor, China Medical University, Taichung, Taiwan
05/08 - Chief Executive Officer, China Medical University Healthcare System, Taichung, Taiwan
01/09 - Editor-in-Chief, Mid-Taiwan Journal of Medicine

Ischemic (stroke) and traumatic (spinal cord injury) injuries of the nervous system and age-dependent degeneration of the
cerebral blood vessels.

1991-1998, Javits Neuroscience Investigator Award (NIH-NINDS)
1993-, Dana Alliance for Brain Initiatives, Member
1997, Taiwanese-American Foundation Science and Technology Award
1996, Leadership Award (Awarded to The Stroke Management and Rehabilitation Team which is directed by CY Hsu),
1993-1994, Vivian L. Smith Foundation Distinguished Research Award
1983-88, NINDS Teacher-Investigator Development Award
1978,1980, National Research Service Award
1975-77, NIH Fellowship
1971-75, Graduate Fellowship, Department of Pharmacology, University of Virginia
1985, Nominated for MUSC Golden Apple Award (Excellence in Teaching)
1986, August, Selected by Patient Representatives and Honored by MUSC for Excellence in Patient Service

Book or Monograph Editor:

Hsu CY (ed.): Cerebral Ischemia: From basic mechanisms to new drug developments, Karger, AG, Basel, 1998. Choi DW (ed), Dacey R, Hsu CY, Powers WJ (co-eds): Proceeding of the 21st Princeton Conference on Cerebrovascular Disease, 1998, American Heart Association, Anderson DK, Hsu CY, Michel MB, Stokes BT (eds): NIH Workshop on Experimental Spinal Cord Injury: Modeling and Criteria, J Neurotrauma, Vol. 9, Issue #2, 1992. Wei YH, Lee HM, Hsu CY (eds.): The role of mitochondria in human aging and disease. Ann NY Acad Sci, Vol 1042, 2005.
Journal Editorial Boards:

1993-2006, Stroke
1996-, Journal of Cerebral Blood Flow and Metabolism
2002-2005, Brain Research
1989, Journal of Neurotrauma
1997-2003, Clinical Neuropharmacology
2003-, Current Neurovascular Research
1993-, Journal Formosan Medical Association (Guest Editorial Board)
中國醫藥大學 臨床醫學研究所 Graduate Institue of Clinical Medical Science, China Medical University 2000-, Journal of Medical Ethics and Humanities (Taiwan)
2002-, Acta Neurologica Taiwanica
2002-, Cerebrovascular Diseases Foreign Medical Sciences
2008-, Surgical Neurology, Taiwan Supplement

Reviewer, Neuroscience Grant Proposals Administered by the Catalan Agency for Health Technology Assessment and
Research (CAHTA), Spain, 2006
Reviewer, Biomedical Research Council and National Medical Research Council, Singapore, 2005
Reviewer, Swiss National Science Foundation, 2002.
Reviewer, Scientific Program Abstracts, International Advisory Board, the 19th, 20th and 21st International Symposium on
Cerebral Blood Flow and Metabolism (Brain 1999, Brain 2001 and Brain 2005).
External Reviewer, International Human Frontier Science Program, Bureaux Europe, Strasbourg, France, 1998-
International Reviewer, New Zealand Neurological Foundation, 1998-
Ad Hoc Abstract Reviewer: American Academy of Neurology Meeting, 1991-1998.
Reviewer for Quality Standards Subcommittee, Practice Committee, American Academy of Neurology on practice
parameter of t-PA therapy for ischemic stroke, April, 1996 and on prevention of stroke in patients with nonvalvular atrial
fibrillation, October, 1996.
Member, Abstract Review Panel, the International Joint Conferences on Stroke and Cerebral Circulation. 1996-1997,
1997-1998, 1998-1999, 1999, 2000 - 2002.

Ad Hoc Journal Reviewer:

American Journal of PhysiologyAnnals of Neurology, Archives of Neurology, Behavioral Brain Research, Brain
Research, Clinical Biochemistry, Circulation, Circulation Research, Critical Care Medicine, European Journal of
Neuroscience, Experimental Neurology, FASEB Journal, Glia, Journal of Cell Physiology, Journal of Applied
Physiology, Journal of Clinical Investigation, Journal of Comparative Neurology, Journal of Neurochemistry, Journal of
Neuroscience, Journal of Neuroscience Methods, Journal of Neuroscience Research, Journal of Neurosurgery, Journal
of Pharmacology and Experimental Therapeutics, Journal of Thoracic and Cardiovascular Surgery, Life Sciences,
Molecular Brain Research, Molecular and Chemical Neuropathology, Molecular Medicine, Neurobiology of Disease,
Neurology, Neuron, Neuroscience Letters, Neuroscience Research, Restorative Neurology and Neuroscience,
Proceeding National Academy of Science USA, Science.
Ad Hoc Member: NIH Neurological Disorder Program Project Review B Committee, NIH Immunological Sciences
Study Section, Neurology B Study Section, Neurological Science - 1 Study Section. NIH-NICHD National Center for
Medical Rehabilitation and Research Special Review Committee, NIHLB Special Review Committee, VA Merit
Review, Paralyzed Veterans of America, American Paralysis Association, Alzheimer’s Association, Henry Ford
Hospital Stroke Research Projects, State of Virginia Biotechnology Research Project, Army neurotrauma research
projects and neurotoxin exposure rescue program 1997 - 2000 (conducted by American Institute of Biological Sciences),
Allegheny University of the Health Sciences, New Zealand Neuroscience Foundation, Human Frontier Science
Member, Ad Hoc Committee on Scientific Conduct, University of California, San Francisco, May 1989.

PUBLICATIONS (Selected from 265 research articles, 4 books):
1. Selected Basci Science Articles:
Hsu CY, Brooker G, Peach MJ, Westfall TC: Inhibition of catecholamine release by tolbutamide. Science
187:1086-88, 1975.
Gibbs JBN, Hsu CY, Terasaki WL, Brooker G: Calcium sensitivity and microtubular dependence of ornithine
decarboxylase induction by cyclic AMP and independent mechanisms. Proc Nat Acad Sci USA 77:995-99, 1980.
An G, Lin TN, Liu JS, He YY, Xue JJ, Hsu CY: Expression of c-fos and c-jun after cerebral ischemia. Ann Neurol
33:457-464, 1993.
Liu PK, Salminen A, He YY, Jiang MH, Xue JJ, Liu JS, Hsu CY: Suppression of ischemia-induced Fos expression and AP-1 activity by an antisense oligodeoxynucleotide to c-fos mRNA. Ann Neurol 36:566-576, 1994.
Koh JY, Suh SW, Gwag BJ, He YY, Hsu CY, Choi DW: The role of zinc in neuronal death after transient global
cerebral ischemia. Science, 272:1013-1016, 1996.
Liu PK, Hsu CY, Dizdaroglu M, Floyd RA, Kow YW, Karakaya A, Rabow LE, Cui JK: Damage, repair, and
mutagenesis in nuclear gene after mouse forebrain ischemia and reperfusion. J Neurosci, 16(21):6795-6806,
中國醫藥大學 臨床醫學研究所 Graduate Institue of Clinical Medical Science, China Medical University Liu XZ, Xu XM, Hu R, Du C, Shang SX, McDonald JW, Dong HX, Wu YJ, Fan GS, Jacquin MF, Hsu CY, Choi
DW: Neuronal and glial apoptosis after traumatic spinal cord injury. J Neurosci., 5395-5406. 1997.
Yamada KA, Covey DF, Hsu CY, Hu R, Hu Y, He YY: The diazoxide derivative IDRA 21 enhances ischemic
hippocampal neuron injury. Ann Neurol 43:664-669, 1998.
10. Yeh H-J, He YY, Xu J, Hsu CY, Deuel TF: Upregulation of pleiotrophin (ptn) gene expression in microvasculature, macrophage, and astrocyte on acute ischemic brain injury in the rat. J Neurosci 18:3699-3707,
11. Xu J, Yeh CH, Chen SW, He L, Sensi SL, Canzoniero LMT, Choi DW, Hsu CY: Involvement of de novo ceramide biosynthesis in TNF-a/cycloheximide-induced cerebral endothelial cell death. J Biol Chem
273:16521-16526, 1998.
12. Huang SS, Huang FW, Chen SW, Xu J, Hsu CY, Huang JS: Amyloid -peptide possesses a transforming growth factor- activity. J Biol Chem 273: 27640-27644, 1998.
13. Cui JK, Hsu CY, Liu PK: Suppression of post-ischemic hippocampal NGF expression by a c-fos antisense oligodeoxynucleotide. J Neurosci, 19:1335-1344, 1999.
14. Yan P, Chen SW, Kim GM, Xu J, Hsu CY, Xu XM: Expression of glucocorticoid receptor after traumatic spinal cord injury. J Neurosci, 19:9355-9363, 1999.
15. Xu J, Chen SW, Ahmed SH, Chen H, Ku G, Goldberg MP, Hsu CY: Amyloid- peptides are cytotoxic to oligodendrocytes. J Neurosci 21:RC118:1-5, 2001.
16. Holtzman DM, Han BH, He YY, Kim GM, Choi JJ, Hsu CY: Inhibition of post-ischemic brain injury by clusterin overexpression. Nature Med (Letter) 7:978-979, 20001.
17. Xu J, Kim GM, Ahmed SH, Xu JM, Yan P, Xu XM, Hsu CY: Glucocorticoid receptor-mediated suppression of AP-1 activation and matrix metalloproteinase expression after spinal cord injury. J Neurosci 21: 92-97, 2001.
18. Kim GM, Xu J, Xu JM, Song SK, Yan P, Ku G, Xu XM, Hsu CY: TNF receptor deletion reducesNF- B activation, c-IAP2 expression and functional recovery after traumatic spinal cord injury. J Neurosci 21:
6617-6625, 2001.
19. Liu PK, Grossman RG, Hsu CY, Robertson GS: Ischemic Injury and Faulty Gene Transcripts in the Brain. Trends Neursci 24:581-588, 2001.
20. Yin KJ, Lee JM, Chen SD, Xu J, Hsu CY: Amyloid beta induces Smac release via AP-1/Bim activation. J
Neurosci 22:9764-9770, 2002.
21. Lee JM, Vo K, Hongyu, Hsu CY, Lin WL: MR cerebral metabolic rate of oxygen utilization in hyperacute patients. Ann Neurol 53:227-232, 2003.
22. Lee JM, Yin KJ, Hsin I, Chen, Fryer JD, Holtzman D, Hsu CY, Xu J: A Role for Matrix Metalloproteinase-9 in Cerebral Amyloid Angiopathy-related Hemorrhage. Ann Neurol, 54:379-382, 2003.
23. Lee JT, Xu J, Lee JM, Ku G, Han XL, Yang DI, Chen SW, Hsu CY: Amyloid-b pe oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway. J Cell Biol 164:123-131,
24. Yin KJ, Hsu CY, Hu XY, Chen H, Chen SW, Xu J, Lee JM. PP2A regulates bim expression via the Akt/FKHRL1 signaling pathway in A -induced cerebrovascular endothelial cell death. J Neurosci, 26: 2290-2299, 2006.
atrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J Biol
281:24566-24574, 2006
l, Matrix metalloproteinases expressed by astrocytes mediate extracellular
A-beta catabolism. J Neurosci 26:10939-10948, 2006
27. Hsu MJ, Hsu CY, Chen BC, Chen MC, Ou G, Lin CH. ASK1 in Amyloid β  peptide-induced cerebral endothelial cell apoptosis. J Neurosci, 27:5719-5729, 2007
28. Lee JM, Yan P, Xiao Q, Chen S, Lee KY, Hsu CY, Xu J. Methylprednisolone protects oligodendrocytes but not neurons after spinal cord injury. J Neurosci. 28:3141-3149, 2008.

2. Selected Clinical Trial Articles:

29. Hsu CY, Faught RE, Furlan AJ, Coull BM, Huang DC, Hogan EL, Linet OI, Yatsu FM for Prostacyclin Study
Group: Intravenous prostacyclin in acute non-hemorrhagic stroke--A placebo-controlled double blind trial. Stroke
18:353-358, 1987.
30. Hsu CY, Norris JW, Hogan EL, Bladin P, Dinsdale HB, Yatsu FM, Earnest MP, et. al: Pentoxifylline in acute nonhemorrhagic stroke--a randomized, placebo-controlled double blind trial. Stroke 19:716-23, 1988.
31. The American Nimodipine Study Group: Clinical trial of nimodipine in acute ischemic stroke. Stroke 23:3-8,
32. Publications Committee for the trial of Org 10172 in Acute Stroke Treatment(TOAST) Investigators. Low molecular weight heparinoid, Org 10172, and outcome after acute ischemic stroke. A randomized controlled trial.
JAMA 279:474-481, 1998.
中國醫藥大學 臨床醫學研究所 Graduate Institue of Clinical Medical Science, China Medical University 33. Clark W, Wissman S, Albers G, Jhamandas J, Madden K, Hamilton S for the ATLANTIS Study Investigators: The ATLANTIS Study: recombinant tissue plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours
after symptoms onset. A randomized, double-blind, placebo-controlled trial. JAMA 282:2019-2026, 1999
34. Sherman DG, Atkinson R, Chippendale T, Levin K, Ng K, Futrell N, Hsu CY, Levy DE for STAT Investigators: Ancrod improves functional outcome in patients with acute ischemic stroke: Results of the stroke treatment with
ancrod trial (stat). JAMA 283:2395-2403, 2000.
35. Sacco RL, DeRosa JT, Haley EC, Levin B, Ordronneau P, Phillips SJ, Rundek T, Snipes RG, Thompson JLP for the GAIN American Investigators: Glycine antagonist in neuroprotection for patients with acute stroke: GAIN
Americans: A randomized controlled trial. JAMA 285:1719-1728, 2001.
Aspirin and ticlopidine for prevention of recurrent stroke in
black patients: a randomized trial. JAMA 289:2947-2957, 2003.

3. Selected Monographs:
37. Hsu CY (ed.): Cerebral Ischemia: From basic mechanisms to new drug development, Karger, AG, Basel, 1998.
38. Wei YH, Lee HM, Hsu CY (eds.): The role of mitochondria in human aging and disease. Ann NY Acad Sci, Vol

NIH and Other government grant supports in the past 5 years in US dolloars)
Cell-cell interactions and hypoxic brain injury, (PO-1 NS32636) PI, CY Hsu (15%), 12/1/00 - 11/30/05, US$1,500,000 approximate total costs/year for the entire Program Project Grant, approximate total:US $7,000,000. (Transferred to Dr. Mark Goldberg) Amyloid-induced cerebroendothelial degeneration in aging (RO-1 NS40525), PI, CY Hsu (20%), 7/1/00 – 6/30/2005, US$384,000 total costs/year, approximate total: US$1,890,000. (Transferred to Dr. Jin-Moo Lee) Methylprednisolone treatment of spinal cord injury, (RO-1, NS40162), PI, CY Hsu (20%), 11/1/00 – 10/31/05, US$320,000 total costs/year, approximate total: US$1,600,000. (Transferred to Dr. Jan Xu). Inflammatory Apoptosis after Spinal Cord Injury, RO1, (RO-1 NS37230), PI, CY Hsu (15% effort), 9/1/97-8/31/03, US$288,000 total costs/year, approximate total: US$1,560,000. ES Cell Transplantation After Spinal Cord Injury Program Project (PO-1 NS39577), PPG PI: Johnson EM; Core B PI: CY Hsu (10%): 12/1/99 – 11/30/04, US$155,268 total costs/year for Core B, approximate total: US$776,340. Vitamin Intervention for Stroke Prevention (RO-1 NS 34447), PIs, JF Toole and V Howard; Wash U PI, CY Hsu (2%) 8/1/98 - 7/31/04, US$65,000 total costs/year, approximate total: US$260,000. NIH African American Aspirin Stroke Prevention Study: PI, P. Gorelick, Wash U PI, CY Hsu (8.5% effort), approximately US$60,000/ year direct, $90,000/year total, 6/1/96-5/31/04, approximate total: US$630,000 Stroke Prevention Center Grant, Ministry of Health (Taiwan), PI, CY Hsu (5%): 1/03 – 12/ 05, US$ 300,000, total costs. Amyloid-induced cerebral vascular degeneration PPG, National Science Council (Taiwan), PI, CY Hsu, 8/03 – 7/06, US$400, 000, total costs. 10. Genetic mechanism of methylprednisolone neuroprotection, National Genomic Medicince PPG, National Science Council (Taiwan), PI, CY Hsu, 5/04 – 4/07, US$ 1,500,000, total costs. 11. OxLDL cyotoxicity in cerebral endothelial cells PPG, National Science Council (Taiwan), PI, CY Hsu, 8/04 – 12. Clinical Research Center of Excellence grant, Ministry of Health (Taiwan), PI, CY Hsu, 8/05 – 7/10,US $3,000,000, 13. Stroke Center Registry, Ministry of Health (Taiwan), PI, CY Hsu, 1/06 – 12/07, US$ 250,000 with US$250,000 matching funds from Dr. Chi-Chin Huang Stroke Center Foundation. 14. Topnotch Stroke Research Center, Ministry of Education (Taiwan), PI, CY Hsu, 1/1/06 – 12/07, $3,000,000, total 15. M-Taiwan Subproject, Ministry of Economy (Taiwan), TMU PI, CY Hsu, 1/06 – 12/07, US$800,000, total costs for 16. NHIP Pilot Project, Department of Health, PI, Hsu CY, 12/07-11/08, US$450,000. 17. National Health Informatics Platform (NHIP) grant, Ministry of Health (Taiwan), PI, CY Hsu, 1/08 – 12/08, US$ 18. Genetic predisposition to stroke, National Science Council (Taiwan), PI, CY Hsu, 8/08 – 7/10, US$82,500 19. TMU-NIH/NINDS International Collaborative Research on Stroke, National Science Council (Taiwan), PI, CY Hsu, 20. Amyloid-mediated Cerebrovascular Degeneration, National Science Council (Taiwan), 8/08 – 7/11, US$ 106,817 中國醫藥大學 臨床醫學研究所 Graduate Institue of Clinical Medical Science, China Medical University


Microsoft word - newsletter no. 5_april 2011_approvals.docx

Approvals Navotek Medical Receives 510(k) Clearance for Radiation Therapy System Israel-based device developer Navotek Medical, Ltd. has received 510(k) clearance from the FDA for its RealEye monitoring device. The RealEye system is designed to help doctors accurately monitor the delivery of radiation therapy, according the company. Valeritas Receives 510(k) Clearance for Insulin Deliver

Microsoft word - colitisheilung-5

Colitis ulcerosa - Ein erfolgreicher Heilungsprozess und konkrete Hinweise zur Genesung. Wilhelm Roth – Heilpraktiker, Körpertherapeut, Paartherapeut Im Jahr 1991 erkrankte ich schwer an einer Colitis ulcerosa, wurde über 4 Jahre bis in das Jahr 1994 immer wieder mit massiven Kolitisschüben belastet, war mehrmals im Krankenhaus, ich ließ mich ein auf die Unterstützung Anthroposophischer

Copyright © 2010 Medicament Inoculation Pdf